Information on the Target
Abris CEE Mid-Market III LP fund, managed by Abris Capital Partners, has entered into an agreement to acquire 100% of Scanmed S.A., a Poland-based operator of a comprehensive healthcare network. This acquisition from Life Healthcare Group Holdings Limited is currently pending regulatory approvals, with an expected closure in the first quarter of 2021.
For over a decade, Scanmed has provided extensive healthcare services, featuring advanced medical technologies and highly skilled specialists to ensure effective patient recovery. The network operates across 42 locations in Poland, delivering a range of services including primary healthcare, specialist consultations, advanced diagnostics, and hospital treatment.
Industry Overview in Poland
The healthcare industry in Poland is experiencing significant transformation driven by economic growth, demographic changes, and technological advancements. With a rapidly aging population, the demand for high-quality healthcare services is surging, prompting increased government and private sector investment in the health sector.
Healthcare spending has risen considerably, aimed at enhancing service quality and expanding the comprehensiveness of care offered to patients. This upward trend in investment is reflected in the growing number of medical facilities and the enhancement of existing healthcare offerings, showcasing an industry moving towards modernization and efficiency.
Moreover, the Polish government's aspiration to improve healthcare infrastructure aligns with ongoing reforms to increase access to healthcare services across the nation. As a result, healthcare providers are motivated to expand their services and geographic reach to cater to diverse patient needs.
As the sector evolves, there is a particular emphasis on specialized medical care, with areas such as orthopedics, cardiology, and diagnostics experiencing notable growth. These developments create a robust environment for private equity investors looking to capitalize on the evolving landscape of healthcare in Poland.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
The Rationale Behind the Deal
Abris Capital Partners acknowledges the strong fundamentals of the healthcare sector in Poland, marked by a growing elderly population and escalating healthcare expenditures. The firm’s decision to invest in Scanmed underscores its strategic goal to enhance the company’s service offerings and geographic coverage.
By backing Scanmed, Abris plans to improve the organization's medical facilities and expand its operations into crucial therapeutic areas. The investor envisions increasing revenue streams in specialized fields such as orthopedics, ophthalmology, rehabilitation, and urogynecology while establishing new laboratories and surgical units, thus enhancing overall patient care.
Information About the Investor
Abris Capital Partners is a prominent private equity investor focusing on the Central European market. With a successful track record of investments in the healthcare sector, Abris has demonstrated its commitment to driving growth and operational excellence in the companies it partners with.
The firm has a history of strategic investments in healthcare, including notable ventures such as ITP S.A., a vendor of innovative aesthetic medical products, and Dentotal Protect, Romania's leading distributor of dental supplies. By leveraging its expertise in the region, Abris aims to help Scanmed strengthen its market position and foster innovation within its services.
View of Dealert
The acquisition of Scanmed by Abris Capital Partners appears to be a promising investment opportunity. Abris's proactive plans to amplify Scanmed's service range and operational capacity align with current market growth trends in the Polish healthcare industry.
By investing in a well-established network like Scanmed, which has demonstrated resilience and adaptability, Abris is well-positioned to reap significant returns as the demand for enhanced healthcare services continues to rise.
The orientation of Abris towards specializations such as orthopedics and rehabilitation suggests a forward-thinking approach in addressing specific patient needs, making this investment a potentially lucrative venture in the long run.
Overall, the strategic direction outlined by Abris for Scanmed emphasizes the importance of fostering quality healthcare services in Poland, potentially leading to strong growth and a prominent market position in the burgeoning healthcare sector.
Similar Deals
American Heart of Poland → Scanmed Group
2024
Abris Capital Partners → Ars Medical
2022
Karo Healthcare → Perrigo’s Dermacosmetics portfolio
2026
INVL Private Equity Fund II, IFC, Accession Capital Partners → POLMED
2025
Management team of Sterimed, IK Partners, Sagard, Les Amis de Sterimed → Sterimed
2025
Capitala Group → Novellum Longevity
2025
Mable Health Inc. → The Medicus Group
2024
Abris Capital Partners
invested in
Scanmed S.A.
in 2020
in a Management Buyout (MBO) deal